Table 1.
Characteristics of included papers (n = 22).
| Author and year | Country | Study design/study period | Timing of HTN measurement | Study setting/data source | Source population/HDP | HTN definition criteria | Sample size(n) | Effect measures |
|---|---|---|---|---|---|---|---|---|
| Amougou et al. (57) | Cameroon | Retrospective cohort 2009–2016 | 8 years | Records review | PE | Unclear | 136 | Persistent HTN 32/136 (23.5%) |
| Babah et al. (48) | Nigeria | Prospective cohort 2009 | 6 weeks | Labour wards | GH/PE | ACOG | 29 | Persistent HTN 3/29 (10.3%) |
| Cho et al. (58) | Korea | Retrospective cohort 2004–2012 | 8 years | Records review | PE | ISSHP | 1,910 | Persistent HTN 148/1,910 (7.7%) |
| Fadalallah et al. (15) | Sudan | Prospective cohort 2014 | 6 weeks | ANC | PE | ISSHP | 165 | Persistent HTN 58/165 (35.2%) |
| Tornes et al. (66) | Cuba | Prospective cohort 2017–2020 | 1 year | Labour wards | PE | ACOG | 162 | Persistent HTN 45/162 (27.8%) |
| Ishaku et al. (35) | Nigeria | Prospective cohort 2017–2018 | 9 weeks, 6 months and 1 year | ANC/Labour wards | GH/PE/EC | ISSHP | 278 | persistent HTN; GH = 64/278, 23% (9 weeks), 62/278, 22.3% (6 months), 62/278, 22.3% (12 months) PE/EC = 170/278, 62% (9 weeks), 170/278, 62% (6 months) and 173/278, 61.2% (12 months) |
| Kaze et al. (14) | Cameroon | Prospective cohort 2010–2012 | 6 weeks, 3 months and 6 months | ANC/Maternity unit | PE/EC | ISSHP | 54 | Persistent HTN 23/54, 42.6% (6 weeks), 15/54, 27.8% (3 months) 8/54, 14.8% (6 months) |
| Keepanasseril et al. (50) | India | Prospective cohort 2018–2019 | 3 months | Records review | PE | ACOG | 32 | Persistent HTN 32 (18.1%) |
| Lugobe et al. (64) | Uganda | Prospective cohort 2019 | 3 months | Labour ward | PE/EC/GH | Unclear | 111 | Persistent HTN 21/54 (39%) |
| Ma and Yao (51) | China | Prospective cohort 2014–2015 | 6 weeks | ANC | PE | ISSHP | 173 | Persistent HTN 61/173 (35.3%) |
| Mooij et al. (62) | Tanzania | Cross-sectional 2011–2018 | 7 years | Records review | PE | ISSHP | 24 | Persistent HTN 7/24 (29%) |
| Muteke et al. (65) | Uganda | 2017–2018 | 6 weeks | Prospective cohort | PE | ACOG | 85 | Persistent HTN 5/73 (6.9%) |
| Nakimuli et al. (56) | Uganda | Prospective cohort 2009–2011 | 3 months | ANC/labour/postnatal ward | PE/EC | ISSHP | 188 | Persistent HTN 64/188 (34%) |
| Ndayambagye et al. (52) | Uganda | Prospective cohort 2008–2009 | 6 weeks | Labour/postnatal clinics | PE/EC | ISSHP | 195 | Persistent HTN 44/195 (27.7%) |
| Nganou-Gnindjio et al. (63) | Cameroon | Cross-sectional 2011–2016 | 6 months | Records review | PE/EC | Unclear | 92 | Persistent HTN 30/92 (32.6%) |
| Ntlemo et al. (55) | South Africa | Prospective cohort 2019–2020 | 6 weeks | ANC/labour wards | PE | ISSHP | 150 | Persistent HTN 49/150 (32.7%) |
| Olagbuji et al. (53) | Nigeria | Prospective cohort 2009–2010 | 6 weeks | Prenatal | GH/PE/EC | ISSHP | 198 | Persistent HTN 51/198 (25.8%) |
| Osoti et al. (54) | Kenya | Prospective cohort 2016–2018 | 6 months | ANC/labour wards | GH/PE | ISSHP | 63 | Persistent HTN 28/63 (44.4%) |
| Shahbazian et al. (59) | Iran | Retrospective cohort 2001–2003 | 5 years | Records review | PE | ISSHP | 35 | Persistent HTN 10/35 (28.6%) |
| Shammas (60) | Jordan | Retrospective cohort 1988–1998 | 10 years | Records review | PE/GH | Unclear | 101 | Persistent HTN 11/47 (23%) for PE, 21/54 (39%) for GH |
| Sukmanee et al. (16) | Thailand | Nested cross-sectional 2014–2020 | 7 years | Records review | PE | ISSHP | 88 | Persistent HTN 28/88 (31.8%) |
| Wang et al. (61) | China | Retrospective cohort 2014–2020 | 2 years | Records review | PE/GH/EC | ESH-ESC | 1,261 | Persistent HTN 94/1,261 (7.5%) |
PE, preeclampsia; GH, Gestational hypertension; EC, Eclapmsia; HTN, hypertension; HDP, hypertensive disorders of pregnancy; ANC, antenatal care; ISSHP, International Society for the Study of Hypertension in Pregnancy; ACOG, American College of Obstetrician and Gynaecologists; ESH–ESC, European Society of Hypertension–European Society of Cardiology.